Bepirovirsen Functional Cure Durable Through Week 96 in Chronic Hepatitis B

A phase 3 clinical trial has shown that the drug bepirovirsen provides a durable functional cure for chronic hepatitis B in 91% of responders. The study results, presented at AASLD The Liver Meeting 2026, confirm the long-term efficacy of the treatment 48 weeks after stopping all therapy.
Why it matters
This represents a significant medical breakthrough for chronic HBV management, offering a potential path to long-term remission for patients without cirrhosis.
Functional cure achieved with 24 weeks of bepirovirsen was durable in 91% of responders with chronic hepatitis B virus (HBV) infection through Week 96, 48 weeks after stopping all HBV treatment, according to end-of-study results from the phase 3 B-Well 1 and B-Well 2 trials presented at AASLD The Liver Meeting 2026.¹
Man-Fung Yuen, MD, PhD, of the University of Hong Kong, presented the data. The US Food and Drug Administration approved bepirovirsen (Hibsago) on October 20, 2026, as the first antisense oligonucleotide for chronic HBV infection, for use with nucleos(t)ide analog (NA) therapy in adults without cirrhosis and hepatitis B surface antigen (HBsAg) of 3000 IU/mL or less.³
How Durable Was Functional Cure With Bepirovirsen?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in